MetaVia, an affiliate of Dong-A ST (170900.KS), will unveil research achievements on its obesity and metabolic disease drug candidates on the global stage.
MetaVia announced Wednesday that research results for its GLP-1/glucagon dual-acting obesity treatment "DA-1726" and metabolic dysfunction-associated steatohepatitis (MASH) treatment "Vanoglipel (DA-1241)" have been selected as Late-Breaking Abstracts (LBA) for the American Diabetes Association (ADA) Scientific Sessions, with a total of three poster presentations to be conducted.
The ADA is a globally authoritative academic conference where the latest research findings in metabolic diseases such as diabetes, obesity and MASH are shared. This year's conference will be held June 5-8 in New Orleans, Louisiana.
Research results for the obesity treatment DA-1726 will be presented by Chris Fang, MetaVia's Chief Medical Officer (CMO). The presentation topic is "Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of DA-1726, an Oxyntomodulin Analogue: Phase 1 Higher-Dose Cohort Results."
DA-1726 is an oxyntomodulin analogue-class obesity treatment that simultaneously acts on GLP-1 receptors and glucagon receptors. It is a candidate substance that induces weight loss and blood glucose control effects through appetite suppression, insulin secretion promotion and increased basal metabolic rate.
Research related to the MASH treatment Vanoglipel will be presented by Chae Yu-na, leader of the Discovery Biology 2 Team at Dong-A ST's Drug Discovery Lab, and Kim Tae-hyung, principal researcher, respectively.
Team leader Chae will introduce research results on the topic of "Synergistic Hepatoprotective and Weight-Loss Effects of Vanoglipel and Resmetirom Combination Therapy in a Diet-Induced Obese, Biopsy-Confirmed Mouse Model of MASH."
Principal researcher Kim will present "Synergistic Effects of Vanoglipel and Metformin on Glycemic Control and Body Weight Reduction in a Diet-Induced Obese Mouse Model."
Vanoglipel is a first-in-class oral synthetic drug candidate based on the GPR119 mechanism of action, being developed as a treatment for MASH and type 2 diabetes. Animal studies have confirmed effects on improving blood glucose and lipids along with improving liver inflammation and fibrosis, while a global Phase 2a trial demonstrated hepatoprotective and glycemic control effects.
"With the research results of DA-1726 and Vanoglipel being selected as Late-Breaking Abstracts at the globally authoritative American Diabetes Association, we have been able to widely promote the competitiveness of MetaVia's metabolic disease pipeline," MetaVia CEO Kim Hyung-heon said. "Based on the differentiated competitiveness of DA-1726 and Vanoglipel, we will develop them into innovative treatment options in metabolic disease fields such as obesity and MASH."
Meanwhile, MetaVia serves as the global research and development (R&D) outpost of the Dong-A Socio Group, and is developing the obesity treatment DA-1726 and the MASH treatment Vanoglipel, among others. The company is also expanding strategic partnership opportunities by introducing its corporate competitiveness and growth strategies to global investors.
